In 2016, Novartis launched the Novartis Access program in Kenya to provide a basket of 15 medicines for non-communicable diseases (NCDs) to governments, NGOs and other institutional customers in lower-income countries at a price of USD 1 per treatment per month. To measure and evaluate (M&E) the social outcomes of the access initiative, we commissioned a team of researchers at Boston University School of Public Health (BUSPH) to undertake an independent evaluation.
Building on the midterm results presented in our last year’s MA Webinar on Evaluating Social Materiality by Measuring Outcomes, the upcoming edition will showcase how the methodology has evolved, critically reflect on the end line results and illustrate how our M&E work allows us to factually inform the dialogue with relevant stakeholders about successes and failures in advancing access to medicine – one of our key material issue clusters. The innovative evaluation method has unique strengths due to its use of multiple complementary methods such as a cluster-randomized controlled trial, serial qualitative interviews and telephonic monitoring. If you like to dig deeper into our M&E efforts, please browse the official BUSPH Evaluation of Novartis Access Website for the many documents and publications about the evaluations and the project that have been posted.
On October 28, we are delighted that Profs. Richard Laing and Monica Onyango, investigators of our evaluation of Novartis Access from the Boston University School of Public Health, will join us and set the scene. They will walk us through the end line results of the M&E work in Kenya and embed it into the global context. This combined presentation will highlight the value of combining quantitative and qualitative methods to understand the what and the why of an evaluation. Dr. Michael Fürst, our Head Social Innovation & Strategy, will highlight the value of qualitative methods to strengthen M&E to better understand the materiality of our interventions and Kileken ole-MoiYoi, Global Head Strategy & CR Initiatives , will outline future developments of Novartis Access.
As an important stakeholder to Novartis, we hope you can join the conversation and support the discussions with your thoughts and questions.
| Webinar |
Measuring and Evaluating Social Outcomes of Access Initiatives |
| Moderation |
Jeff Sturchio, Chief Executive Officer, Rabin Martin |
Special Guest
|
Prof. Richard Laing, Co-Principal Investigator, Evaluation of Novartis Access, Boston University School of Public Health |
| Special Guest |
Monica A. Onyango, PhD, Clinical Associate Professor, Global Health, Boston University School of Public Health |
| Speaker |
Dr. Michael Fürst, Head Social Innovation & Strategy, Global Health & Corporate Responsibility, Novartis |
| Speaker |
Kileken ole-MoiYoi, Global Head Strategy & CR Initiatives, Global Health & Corporate Responsibility, Novartis |
| |
|
| Date |
Wednesday, October 28, 2020 |
| Time |
14:00-15:00 CET / 13:00-14:00 GMT / 09:00-10:00 EDT |
|